1Neil Binkley MD,Diane Krueger BS, CDT, CCRC. Combination therapy for osteoporosis: Considerations and controversy[J] 2005,Current Osteoporosis Reports(4):150～154
2James G. F. Bolton,Sanjeev Patel,J. Hubert Lacey,Sarah White. A prospective study of changes in bone turnover and bone density associated with regaining weight in women with anorexia nervosa[J] 2005,Osteoporosis International(12):1955～1962
3M. J. Rogers. From Molds and Macrophages to Mevalonate: A Decade of Progress in Understanding the Molecular Mode of Action of Bisphosphonates[J] 2004,Calcified Tissue International(6):451～461
4Alfred A. Reszka PhD,Gideon A. Rodan MD, PhD. Mechanism of action of bisphosphonates[J] 2003,Current Osteoporosis Reports(2):45～52
5Adi Cohen,Elizabeth Shane. Osteoporosis after solid organ and bone marrow transplantation[J] 2003,Osteoporosis International(8):617～630
6B. Hamilton,K. McCoy,H. Taggart. Tolerability and compliance with risedronate in clinical practice[J] 2003,Osteoporosis International(3):259～262
7S. Wallach,S. Cohen,D. M. Reid,R. A. Hughes,D. J. Hosking,R. F. Laan,S. M. Doherty,M. Maricic,C. Rosen,J. Brown,I. Barton,A. A. Chines. Effects of Risedronate Treatment on Bone Density and Vertebral Fracture in Patients on Corticosteroid Therapy[J] 2000,Calcified Tissue International(4):277～285
9LEE S, ROSEN. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma [ J ]. Cancer, 2003,98 ( 8 ) : 1737-17d4.
10HARINCK H I J, PAPAPOULOS S E,BLANKSMA H J,et al. Paget's disease of bone :early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate ( APD ) [ J ]. BMJ, 1987,295 ( 8 ) : 1301 - 1305.
